Further Information
WAS, THC, IMD2, WASP, Wiskott-Aldrich syndrome (eczema-thrombocytopenia), thrombocytopenia 1 (X-linked), Wiskott-Aldrich syndrome (eczema-thrombocytopenia) protein
WB: 1:500 - 1:2000
IF: 1:10 - 1:100
The Wiskott-Aldrich syndrome (WAS) family of proteins share similar domain structure, and are involved in transduction of signals from receptors on the cell surface to the actin cytoskeleton. The presence of a number of different motifs suggests that they are regulated by a number of different stimuli, and interact with multiple proteins. Recent studies have demonstrated that these proteins, directly or indirectly, associate with the small GTPase, Cdc42, known to regulate formation of actin filaments, and the cytoskeletal organizing complex, Arp2/3. Wiskott-Aldrich syndrome is a rare, inherited, X-linked, recessive disease characterized by immune dysregulation and microthrombocytopenia, and is caused by mutations in the WAS gene. The WAS gene product is a cytoplasmic protein, expressed exclusively in hematopoietic cells, which show signalling and cytoskeletal abnormalities in WAS patients. A transcript variant arising as a result of alternative promoter usage, and containing a different 5' UTR sequence, has been described, however, its full-length nature is not known.
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Recombinant fusion protein containing a sequence corresponding to amino acids 60-250 of human WAS (NP_000368.1).
7454
Wiskott-Aldrich syndrome
WAS
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
Observed: 62kDa
Affinity purification
Cell Cycle, Immunology, Signal Transduction
P42768
Optimal dilutions for each application to be determined by the researcher.